Immutep Ltd ( (AU:IMM) ) has issued an announcement.
Immutep Ltd announced a change in the interest of its director, Dr. Frederic Triebel, involving the exchange of 1,800,000 performance rights for fully paid ordinary shares. This change, which was executed without any cash consideration, reflects the vesting and exercising of performance rights approved at the 2021 AGM, increasing Dr. Triebel’s holdings in the company and potentially signaling confidence in the company’s strategic direction.
More about Immutep Ltd
Immutep Ltd is a biotechnology company focused on developing immunotherapy treatments for cancer and autoimmune diseases. The company is known for its work on LAG-3 related products, which are designed to harness the body’s immune system to fight disease.
YTD Price Performance: -9.09%
Average Trading Volume: 5,000
Technical Sentiment Signal: Strong Buy
Current Market Cap: $224M
For an in-depth examination of IMM stock, go to TipRanks’ Stock Analysis page.